GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (MEX:GRF N) » Definitions » Shiller PE Ratio

Grifols (MEX:GRF N) Shiller PE Ratio : (As of Jul. 21, 2025)


View and export this data going back to 2023. Start your Free Trial

What is Grifols Shiller PE Ratio?

Note: If the price history is too short, we do not calculate current Shiller PE for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Grifols Shiller PE Ratio Historical Data

The historical data trend for Grifols's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Shiller PE Ratio Chart

Grifols Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33.86 - 12.77 18.09 10.75

Grifols Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.25 18.09 9.13 12.11 10.75

Competitive Comparison of Grifols's Shiller PE Ratio

For the Drug Manufacturers - General subindustry, Grifols's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grifols's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grifols's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Grifols's Shiller PE Ratio falls into.


;
;

Grifols Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Grifols's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Grifols's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=2.214/124.7533*124.7533
=2.214

Current CPI (Dec. 2024) = 124.7533.

Grifols Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 3.160 100.139 3.937
201406 2.643 101.081 3.262
201409 2.855 100.441 3.546
201412 3.547 100.251 4.414
201503 3.135 99.474 3.932
201506 3.346 101.138 4.127
201509 3.793 99.559 4.753
201512 3.559 100.268 4.428
201603 3.450 98.638 4.363
201606 4.156 100.333 5.168
201609 4.557 99.737 5.700
201612 4.439 101.842 5.438
201703 3.952 100.896 4.886
201706 4.265 101.848 5.224
201709 4.759 101.524 5.848
201712 7.856 102.975 9.517
201803 4.702 102.122 5.744
201806 5.968 104.165 7.148
201809 4.802 103.818 5.770
201812 4.021 104.193 4.814
201903 3.726 103.488 4.492
201906 5.426 104.612 6.471
201909 4.339 103.905 5.210
201912 6.077 105.015 7.219
202003 7.058 103.469 8.510
202006 1.300 104.254 1.556
202009 10.148 103.521 12.229
202012 4.598 104.456 5.491
202103 4.627 104.857 5.505
202106 4.797 107.102 5.588
202112 0.000 111.298 0.000
202206 2.830 118.044 2.991
202209 1.307 117.221 1.391
202212 -0.097 117.650 -0.103
202306 1.114 120.278 1.155
202309 1.632 121.343 1.678
202312 1.541 121.300 1.585
202406 0.394 124.409 0.395
202409 1.662 123.121 1.684
202412 2.214 124.753 2.214

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Grifols  (MEX:GRF N) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Grifols Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Grifols's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Grifols Business Description

Address
Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Grifols Headlines

No Headlines